Acino, a Swiss pharmaceutical company, completed the acquisition of M8 Pharmaceuticals, a specialty biopharmaceutical company, from Montreux Equity Partners, a private equity firm. Financial terms were not disclosed. “This is a transformative deal for Acino, significantly expanding our presence in Latin America and delivering against our overall strategy and stated intention to increase patient’s access to high-quality pharmaceuticals and diversify our footprint in key high-growth markets. We see M8 and Acino as highly complementary offerings, and we are confident that we can use this acquisition as a catalyst to further increase value and accelerate growth for Acino in this key region,” Andrew Bird, Acino Interim CEO.